Role of HSP90 in suppressing TLR4-mediated inflammation in ischemic postconditioning.


Journal

Clinical hemorheology and microcirculation
ISSN: 1875-8622
Titre abrégé: Clin Hemorheol Microcirc
Pays: Netherlands
ID NLM: 9709206

Informations de publication

Date de publication:
2020
Historique:
pubmed: 12 7 2020
medline: 21 11 2020
entrez: 12 7 2020
Statut: ppublish

Résumé

Myocardial inflammation mediated by toll-like receptor 4 (TLR4) plays an active role in myocardial ischemia/reperfusion (I/R) injury. Studies show that heat shock protein 90 (HSP90) is involved in ischemic postconditioning (IPostC) cardioprotection. This study investigates the roles of TLR4 and HSP90 in IPostC. Rats were subjected to 30 min ischemia, then 2 h reperfusion. IPostC was applied by three cycles of 30 s reperfusion, then 30 s reocclusion at reperfusion onset. Sixty rats were randomly divided into four groups: sham, I/R, IPostC, and geldanamycin (GA, HSP90 inhibitor, 1 mg/kg) plus IPostC (IPostC + GA). IPostC significantly reduced I/R-induced infarct size (40.2±2.1% versus 28.4±2.4%; P < 0.05); the release of cardiac Troponin T, creatine kinase-MB, and lactate dehydrogenase (191.5±3.1 versus 140.6±3.3 pg/ml, 3394.6±132.7 versus 2880.7±125.5 pg/ml, 2686.2±98.6 versus 1848.8±90.1 pg/ml, respectively; P < 0.05); and cardiomyocyte apoptosis (40.3±2.2% versus 27.0±1.6%; P < 0.05). Further, local and circulating IL-1β, IL-6, TNF-α, and ICAM-1 levels decreased; TLR4 expression and nuclear factor-KB (NF-κB) signaling decreased; and cardiac HSP90 expression increased. Blocking HSP90 function with GA inhibited IPostC protection and anti-inflammation, suggesting that IPostC has a HSP90-dependent anti-inflammatory effect. HSP90 may play a role in IPostC-mediated cardioprotection by inhibiting TLR4 activation, local and systemic inflammation, and NF-kB signaling.

Sections du résumé

BACKGROUND BACKGROUND
Myocardial inflammation mediated by toll-like receptor 4 (TLR4) plays an active role in myocardial ischemia/reperfusion (I/R) injury. Studies show that heat shock protein 90 (HSP90) is involved in ischemic postconditioning (IPostC) cardioprotection. This study investigates the roles of TLR4 and HSP90 in IPostC.
METHODS METHODS
Rats were subjected to 30 min ischemia, then 2 h reperfusion. IPostC was applied by three cycles of 30 s reperfusion, then 30 s reocclusion at reperfusion onset. Sixty rats were randomly divided into four groups: sham, I/R, IPostC, and geldanamycin (GA, HSP90 inhibitor, 1 mg/kg) plus IPostC (IPostC + GA).
RESULTS RESULTS
IPostC significantly reduced I/R-induced infarct size (40.2±2.1% versus 28.4±2.4%; P < 0.05); the release of cardiac Troponin T, creatine kinase-MB, and lactate dehydrogenase (191.5±3.1 versus 140.6±3.3 pg/ml, 3394.6±132.7 versus 2880.7±125.5 pg/ml, 2686.2±98.6 versus 1848.8±90.1 pg/ml, respectively; P < 0.05); and cardiomyocyte apoptosis (40.3±2.2% versus 27.0±1.6%; P < 0.05). Further, local and circulating IL-1β, IL-6, TNF-α, and ICAM-1 levels decreased; TLR4 expression and nuclear factor-KB (NF-κB) signaling decreased; and cardiac HSP90 expression increased. Blocking HSP90 function with GA inhibited IPostC protection and anti-inflammation, suggesting that IPostC has a HSP90-dependent anti-inflammatory effect.
CONCLUSION CONCLUSIONS
HSP90 may play a role in IPostC-mediated cardioprotection by inhibiting TLR4 activation, local and systemic inflammation, and NF-kB signaling.

Identifiants

pubmed: 32651307
pii: CH200840
doi: 10.3233/CH-200840
doi:

Substances chimiques

HSP90 Heat-Shock Proteins 0
TLR4 protein, human 0
Toll-Like Receptor 4 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-62

Auteurs

Xin-Yue Zhang (XY)

Department of Cardiology, First Affiliated Hospital, Guang Xi Medical University, Nanning, China.

Zheng Huang (Z)

Department of Cardiology, First Affiliated Hospital, Guang Xi Medical University, Nanning, China.

Qing-Jie Li (QJ)

Department of Cardiology, Second Affiliated Hospital, Guang Xi Medical University, Nanning, China.

Guo-Qiang Zhong (GQ)

Department of Cardiology, First Affiliated Hospital, Guang Xi Medical University, Nanning, China.
Guang Xi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Disease Control and Prevention, Nanning, China.
Guang Xi Clinical Research Center for Cardio-cerebrovascular Diseases, Nanning, China.

Jian-Jun Meng (JJ)

Geriatric Healthcare Center, First Affiliated Hospital, Guang Xi Medical University, Nanning, China.

Dong-Xiao Wang (DX)

Department of Cardiology, First Affiliated Hospital, Guang Xi Medical University, Nanning, China.

Rong-Hui Tu (RH)

Guang Xi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Disease Control and Prevention, Nanning, China.
Guang Xi Clinical Research Center for Cardio-cerebrovascular Diseases, Nanning, China.
Department of Geriatric Cardiology, First Affiliated Hospital, Guang Xi Medical University, Nanning, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH